Search our Database of Scientific Publications and Authors

I’m looking for a

    3920 results match your criteria Biology of Blood and Marrow Transplantation[Journal]

    1 OF 79

    Success of Immunosuppressive Treatments in Patients with Chronic Graft-Versus-Host Disease.
    Biol Blood Marrow Transplant 2017 Nov 10. Epub 2017 Nov 10.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medical Oncology, University of Washington, Seattle WA, USA.
    Moderate to severe chronic graft-versus-host disease (GVHD) is treated with potent immunosuppressive therapy (IST) to modulate the allo-immune response, control symptoms and prevent further organ damage. We sought to understand the types of treatments used in clinical practice and the likelihood of successful treatment associated with each. A chart review was performed for 250 adult patients at Fred Hutchinson Cancer Research Center enrolled in a prospective observational study. Read More

    PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-Versus-Host Disease in NOD-Scid IL-2Ry(null) Mice.
    Biol Blood Marrow Transplant 2017 Nov 8. Epub 2017 Nov 8.
    Department of Translational Biology and Oncology Research, The Cleveland Clinic Main Campus, Mail Code 40, 9500 Euclid Avenue, Cleveland OH 44195, 216-445-0548 (P), 216-636-2498 (F). Electronic address:
    Graft-versus-Host Disease (GvHD) is a prevalent and potentially lethal complication of hematopoietic stem cell transplantation (HSCT). Humanized mouse models of xenogeneic-GvHD are important tools used to study the human immune response in vivo. Here we used NOD-scid IL-2Ry(null) mice (NSG) transplanted with human bone marrow stem cells to evaluate the role of immune cell engraftment in the production of acute GvHD. Read More

    Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and CLL.
    Biol Blood Marrow Transplant 2017 Nov 8. Epub 2017 Nov 8.
    Department of Hematology/oncology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY. Electronic address:
    Limited studies have reported on outcomes for lymphoid malignancy patients receiving alternative donor allogeneic stem cell transplants. We have previously described combining CD34-selected haploidentical grafts with umbilical cord blood (haplo-cord) to accelerate neutrophil and platelet engraftment. Here, we examine the outcome of patients with lymphoid malignancies undergoing haplo-cord transplantation at the University of Chicago and Weill Cornell Medical College. Read More

    Immunomodulatory Effects of Tyrosine Kinase Inhibitors (TKIs) in Vitro and in Vivo Study.
    Biol Blood Marrow Transplant 2017 Nov 8. Epub 2017 Nov 8.
    Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy; Clinica di Ematologia, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy. Electronic address:
    Pathogenesis of chronic Graft Versus Host Disease (cGVHD) is incompletely defined, involving donor-derived CD4 and CD8-positive T lymphocytes, as well as B cells. Standard treatment is lacking for steroid dependent/refractory cases; potential usefulness of tyrosine kinase inhibitors (TKIs) has been suggested, based on their potent anti-fibrotic effect. However, TKI seems to have pleiotropic activity. Read More

    Pediatric Hematopoietic Cell Transplant Patients Who Survive Critical Illness Frequently Have Significant but Recoverable Decline in Functional Status.
    Biol Blood Marrow Transplant 2017 Nov 8. Epub 2017 Nov 8.
    George Washington University School of Medicine, Children's National Medical Center, Department of Pediatrics, Division of Critical Care, Washington DC, USA.
    Background: The number of pediatric hematopoietic cell transplant (HCT) patients who survive pediatric intensive care unit (PICU) admission is increasing, yet little is known about their functional morbidity after PICU discharge. We hypothesized that relative to controls, pediatric HCT patients who survive PICU admission would have greater rates of new functional morbidity at the time of PICU discharge, and only a minority of these patients would return to their functional baseline by the end of the hospitalization.

    Methods: We performed a retrospective cohort study with secondary data analysis of the Trichotomous Outcomes in Pediatric Critical Care (TOPICC) dataset. Read More

    Venous Thromboembolism in Pediatric Hematopoietic Cell Transplant: a Multicenter Cohort Study.
    Biol Blood Marrow Transplant 2017 Nov 8. Epub 2017 Nov 8.
    Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, Nationwide Children's Hospital, Columbus, Ohio; Department of Pediatrics, The Ohio State University.
    Introduction: Hematopoietic cell transplant (HCT) is associated with a pro-inflammatory, pro-coagulant environment which places recipients at increased risk of venous thromboembolism (VTE). While the incidence of VTE in adult HCT recipients has been extensively studied, similar data for children are lacking. We conducted a multicenter retrospective study to analyze the prevalence of VTE and associated risk factors in a large cohort of patients who underwent HCT at tertiary-care US children's hospitals. Read More

    Transplant Decisions in Patients with Myelofibrosis: Should Mutations be the Judge?
    Biol Blood Marrow Transplant 2017 Nov 8. Epub 2017 Nov 8.
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA. Electronic address:
    The prognosis of myeloproliferative neoplasms (MPN), including primary myelofibrosis (PMF), polycythemia vera (PV; post-PV MF) and essential thrombocythemia (ET; post-EMF) varies considerably, between these disorders as well as within each diagnosis. Molecular studies have identified "driver mutations", in JAK2, MPL1 and CALR, and additional somatic DNA mutations, including ASXL1, EZH2, IDH1/2 and SRSF2, that affect prognosis differentially. Patients with mutations in CALR (type1) have a better outlook than patients with mutations in JAK2 or MPL, while patients without any of the driver mutations (triple negative) have the shortest life expectancy. Read More

    Cellular Immunotherapy for Haematological Malignancies: Beyond Bone Marrow Transplant.
    Biol Blood Marrow Transplant 2017 Nov 1. Epub 2017 Nov 1.
    Immunotherapy has changed treatment practices for many haematological malignancies. Despite the current era of targeted therapy, chemotherapy remains the backbone of treatment for many haematological malignancies, especially in acute leukaemia, where relapse remains the major cause of mortality. Application of novel immunotherapies in haematology attempts to harness the killing power of the immune system against leukaemia and lymphoma. Read More

    Poor Adherence is Associated with More Infections Following Pediatric Hematopoietic Stem Cell Transplant.
    Biol Blood Marrow Transplant 2017 Nov 1. Epub 2017 Nov 1.
    Department of Pediatrics, University of Cincinnati School of Medicine; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center.
    To prospectively examine rates of outpatient oral medication adherence in children post hematopoietic stem cell transplant (post-HSCT). For six months following first discharge post-HSCT, 50 patients (0 - 16 years-old) and their primary caregivers agreed to store one oral medication in an electronic pill bottle that date and time stamps each bottle opening. Demographics, disease, donor type, and prescribed post-HSCT medication regimen were collected via chart review. Read More

    Post-Transplant Cyclophosphamide (PTCY) as Sole GVHD Prophylaxis is Feasible in Patients Undergoing Peripheral Blood Stem Cell Transplantation for Severe Aplastic Anaemia Using Matched Sibling Donors.
    Biol Blood Marrow Transplant 2017 Oct 31. Epub 2017 Oct 31.
    Department of Haematology, Christian Medical College, Vellore, India.
    High-dose cyclophosphamide (PTCY) following allogeneic hematopoietic cell transplantation (HSCT) has been shown to be effective in preventing graft-versus-host disease (GVHD) following HLA-matched bone marrow transplantation. We performed a phase II study of PTCY given at 50 mg/kg IV on days 3 and 4 as sole GVHD prophylaxis following HSCT for severe aplastic anemia (SAA) receiving G-CSF-mobilized peripheral blood stem cell (PBSC) grafts from HLA-matched related donors following conditioning with fludarabine, cyclophosphamide and single dose Total Body Irradiation (TBI). Read More

    Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival.
    Biol Blood Marrow Transplant 2017 Oct 24. Epub 2017 Oct 24.
    CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Electronic address:
    We compared post-relapse overall survival (OS) after autologous-allogenenic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in multiple myeloma (MM). Post-relapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2000 and 2010 were analyzed. 404 patients (72. Read More

    "C-Reactive Protein Levels at Acute GVHD Diagnosis Predict Steroid-Refractory Disease, Treatment Related Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation".
    Biol Blood Marrow Transplant 2017 Oct 23. Epub 2017 Oct 23.
    Hematopoietic Stem Cell Transplant Unit, Department of Hematology L, section 4041, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Phone: +45 35458373,. Electronic address:
    Acute graft versus host disease (aGVHD) remains an excessive cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Primary treatment consists of high-dose corticosteroids, but a small group of patients develop steroid refractory disease and their prognosis is especially poor. There is experimental evidence that co-existing inflammation aggravates aGVHD. Read More

    Bone Marrow Harvest in Pediatric Sibling Donors: Role of G-CSF Priming and CD34+ Cell Dose.
    Biol Blood Marrow Transplant 2017 Oct 23. Epub 2017 Oct 23.
    Department of Pediatrics, Columbia University, New York.
    To ensure optimal clinical outcomes for patients while retaining adequate protection for donors, the NMDP developed guidelines that state that up to 20 mL/kg of bone marrow can be harvested from donors. These guidelines, developed originally for unrelated adult donors, are followed in children as well. We studied the impact of G-CSF priming on the cellular composition of harvested bone marrow, sought to develop an algorithm to optimize bone marrow harvest volume from pediatric matched siblings, and studied the impact of CD34+ cell dose on clinical outcomes. Read More

    Total Body Irradiation is Safe and Similarly Effective to Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Patients.
    Biol Blood Marrow Transplant 2017 Oct 20. Epub 2017 Oct 20.
    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
    Autologous stem cell transplant (ASCT) consolidation has become a standard approach for patients with mantle cell lymphoma (MCL), yet there is little consensus on the role of total body irradiation (TBI) as part of high-dose transplant conditioning. We analyzed 75 consecutive MCL patients that underwent ASCT at our institution between 2001-2011 with either TBI-based (n=43) or carmustine, etoposide, cytarabine, melphalan (n=32; BEAM) high-dose conditioning. Most patients (97%) had chemosensitive disease and were transplanted in first remission (89%). Read More

    Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as GVHD Prophylaxis.
    Biol Blood Marrow Transplant 2017 Oct 20. Epub 2017 Oct 20.
    Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104; Division of Hematology/Oncology and the Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY 10032. Electronic address:
    Blocking lymphocyte trafficking after allogeneic hematopoietic stem cell transplantation is a promising strategy to prevent graft-versus-host disease (GVHD) while preserving the graft-versus-tumor response. Maraviroc, a CCR5 antagonist, has shown promise in clinical trials, presumably by disrupting the migration of effector cells to GVHD target organs. We describe a phosphoflow assay to quantify CCR5 blockade during treatment with maraviroc and used it to evaluate 28 patients in a phase II study. Read More

    Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.
    Biol Blood Marrow Transplant 2017 Oct 20. Epub 2017 Oct 20.
    Department of Medicine, NewYork-Presbyterian Hospital, New York, New York.
    Administration of granulocyte colony-stimulating factor (G-CSF) after autologous peripheral blood stem cell transplantation (PBSCT) is generally recommended to reduce the duration of severe neutropenia; however, there is limited and conflicting data regarding the optimal timing of G-CSFs post-transplant. A retrospective study was performed at NewYork-Presbyterian/Weill Cornell Medical Center (NYP/WC) from November 5, 2013 to August 9, 2016 of adult inpatient autologous PBSCT patients who received G-CSF empirically starting on day +5 (early) versus day +12 only if absolute neutrophil count (ANC) was <0.5x10(9)/L (ANC driven). Read More

    Homeostatic Γδ T-Cell Contents are Preserved by Granulocyte Colony-Stimulating Factor Priming and Correlate with the Early Recovery of Γδ T Subsets after Haploidentical Hematopoietic Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 20. Epub 2017 Oct 20.
    Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address:
    Emerging evidence from graft manipulations and immunotherapeutic treatments has highlighted a favorable effect of γδ T cells in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT). However, γδ T subsets and their distinct features in the allograft have not been characterized. Additionally, whether homeostatic γδ T-cell fractions are influenced by treatment with granulocyte colony-stimulating factor (G-CSF) remains elusive. Read More

    Outcomes of Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide for Graft- Versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
    Biol Blood Marrow Transplant 2017 Oct 20. Epub 2017 Oct 20.
    Division of Stem Cell Transplant and Regenerative Medicine, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA. Electronic address:
    Unrelated donor (URD) hematopoietic cell transplants (HCT) in children with sickle cell disease (SCD) is associated with a high incidence of rejection and graft versus host disease. We report on first four patients with severe SCD who underwent URD HCT using a novel myeloablative and immunosuppressive regimen comprising of busulfan, fludarabine and anti-thymocyte globulin with a single dose of post-transplant cyclophosphamide along with tacrolimus and mycophenolate mofetil for graft versus host disease prophylaxis. Three patients engrafted and remain disease free after a median follow-up period of 2. Read More

    Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA Haploidentical Transplant with Post-Transplant Cyclophosphamide.
    Biol Blood Marrow Transplant 2017 Oct 18. Epub 2017 Oct 18.
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
    Compared with standard graft-versus-host disease (GVHD) prophylaxis platforms, post-transplantation cyclophosphamide (PTCy) after T cell-replete HLA-haploidentical (haplo) bone marrow transplantation (BMT) reduces the risk of grades III to IV acute (a) and chronic (c) GVHD but maintains similar rates of grade II aGVHD. Given that mild GVHD has been associated with reduced treatment failure in HLA-matched BMT, we evaluated the risk factors for and effects of GVHD on survival in 340 adults with hematologic malignancies who engrafted after nonmyeloablative haplo-BMT with PTCy, mycophenolate mofetil, and tacrolimus. The cumulative incidence at 100 days of grade II and grades III to IV aGVHD were 30% (95% confidence interval [CI], 25% to 35%) and 2% (95% CI, 1% to 4%), respectively. Read More

    Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 16. Epub 2017 Oct 16.
    Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
    Dysgeusia is a frequently occurring symptom after hematopoietic cell transplantation (HCT) that has important long-term effects on physical, nutritional, and immunologic recovery, as well as on quality of life. Despite the relevance of this symptom, the study of dysgeusia patients undergoing HCT has been limited, owing in part to its complexity. In this article, we review normal taste function and its clinical evaluation, discuss how dysgeusia uniquely affects patients undergoing HCT, and examine distinct, transplantation-related contributors to dysgeusia that may help elucidate strategies to ultimately reduce this symptom burden after transplantation. Read More

    Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myelogenous Leukemia: A National Population-Based Cohort Study.
    Biol Blood Marrow Transplant 2017 Oct 16. Epub 2017 Oct 16.
    Department of Hematology, The University Hospital Rigshospitalet, Copenhagen, Denmark. Electronic address:
    To examine the outcomes of allogeneic stem cell transplantation (HSCT) in first complete remission (CR1) compared with chemotherapy alone in a population-based setting, we identified a cohort of patients with acute myelogenous leukemia (AML) aged 15 to 70 years diagnosed between 2000 and 2014 in Denmark. Using the Danish National Acute Leukemia Registry, we compared relapse risk, relapse-free survival (RFS), and overall survival (OS) between patients with unfavorable cytogenetic features receiving postremission therapy with conventional chemotherapy only versus those undergoing HSCT in CR1. To minimize immortal time bias, we performed Cox proportional hazards regression, included date of allogeneic HSCT as a time-dependent covariate, and stratified the results by age (<60 or ≥60 years) and cytogenetic risk group. Read More

    Anti-PDGFRA Antibodies Predict for Response to Nilotinib in Steroid Refractory / Dependent cGvHD.
    Biol Blood Marrow Transplant 2017 Oct 16. Epub 2017 Oct 16.
    Medicine/BMT Division, Stanford University School of Medicine, Stanford, CA. Electronic address:
    Imatinib has clinical activity in chronic graft-versus-host disease (cGvHD), a significant complication of allogeneic hematopoietic cell transplant. Nilotinib is a tyrosine kinase inhibitor that targets the same receptors as imatinib but with different affinities. We tested the hypothesis that nilotinib is safe and has clinical activity in cGvHD. Read More

    Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens.
    Biol Blood Marrow Transplant 2017 Oct 13. Epub 2017 Oct 13.
    Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address:
    Novel induction agents markedly improved remission rates in multiple myeloma (MM), and the continued use of chemotherapy for CD34(+) stem cell mobilization (SCM) has been questioned. We examined the additional effect of chemotherapy in SCM regarding remission status/morbidity. We reviewed 236 consecutive MM patients (aged 36 to 75 years) with first autologous stem cell transplantation from January 2009 to March 2016 after chemotherapy-based SCM. Read More

    Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 14. Epub 2017 Oct 14.
    Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
    Double-expressor lymphoma (DEL) is a diffuse large B cell lymphoma that exhibits co-expression of MYC and BCL2 proteins by immunohistochemistry. Patients with double-expressor lymphoma have a poor prognosis after standard chemoimmunotherapy or after high-dose chemotherapy with autologous transplantation, but the prognostic impact of DEL after allogeneic hematopoietic cell transplantation has not been well characterized. We retrospectively analyzed 60 consecutive patients with de novo diffuse large B cell lymphoma or transformed follicular lymphoma who underwent allogeneic transplantation at our center and had available immunohistochemistry data. Read More

    Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington. Electronic address:
    In a multicenter, prospective,phase II study we evaluated the safety and efficacy of pentostatin followed by donor lymphocyte infusion (DLI) in patients with low donor Tcell chimerism after allogeneic hematopoietic cell transplantation (HCT). Thirty-six patients with low donor blood CD3 chimerism were enrolled in this study. Thirty-five patients received a total of 41 DLIs after a dose of pentostatin, and 1 patient received pentostatin only. Read More

    Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Vanderbilt University, Nashville, Tennessee. Electronic address:
    Chronic graft-versus host disease (GVHD) is a chronic and disabling complication after hematopoietic cell transplantation (HCT). It is important to understand the association of socioeconomic status (SES) with health outcomes in patients with chronic GVHD because of the impaired physical health and dependence on intensive and prolonged health care utilization needs in these patients. We evaluated the association of SES with survival and quality of life (QOL) in a cohort of 421 patients with chronic GVHD enrolled on the Chronic GVHD Consortium Improving Outcomes Assessment study. Read More

    Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Center for International Blood and Marrow Transplantation and Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
    Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplantation (allo-HCT) for medically fit patients. Although the use of allo-HCT has declined since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT, the sole known curative treatment for CLL. Read More

    Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Division of Blood and Marrow Transplantation, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
    Torquetenovirus (TTV) has been proposed as a marker of immune function in patients receiving immunosuppression after solid organ transplantation. This study aimed to define TTV plasma dynamics and investigate clinical associations in patients following allogeneic hematopoietic stem cell transplantation (HSCT). This was a single-center prospective longitudinal study involving 50 consecutive patients treated with HSCT between March 2015 and April 2016. Read More

    Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Biol Blood Marrow Transplant 2017 Oct 13. Epub 2017 Oct 13.
    Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address:
    Large, multicenter studies comparing commonly used reduced-intensity conditioning (RIC) approaches in follicular lymphoma (FL) have not been performed. Using the Center for International Blood and Marrow Transplant Research database, we report the outcomes of the 2 most commonly used RIC approaches, fludarabine and busulfan (Flu/Bu) versus fludarabine, cyclophosphamide, and rituximab (FCR) in FL patients. We evaluated 200 FL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received RIC with either Flu/Bu (n = 98) or FCR (n = 102) during 2008 to 2014. Read More

    A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.
    Biol Blood Marrow Transplant 2017 Oct 13. Epub 2017 Oct 13.
    Hematology and Cell Therapy Unit-IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
    Outpatient autologous stem cell transplantation (ASCT) has proven to be feasible in terms of physical morbidity and mortality outcomes, but little data exist on the impact of this procedure on quality of life (QoL). The purpose of this prospective, observational, longitudinal cohort study was to compare the effects of inpatient (n = 76) and outpatient (n = 64) modes of care on QoL in patients with multiple myeloma who underwent ASCT. Patients were treated according to their preference for the inpatient or outpatient model. Read More

    A European HLA Isolate and Its Implications for Hemeatopooietic Stem Cell Transplant Donor Procurement.
    Biol Blood Marrow Transplant 2017 Oct 13. Epub 2017 Oct 13.
    Finnish Red Cross Blood Service, Helsinki, Finland.
    Europeans have often been considered a homogenous group in registry donor match predictions, but it is now evident that HLA haplotype frequencies vary across the European continent. Earlier studies have indicated that Finns in northeastern Europe have unique HLA characteristics, and the increasing availability of high-resolution registry donor data is now making more detailed comparisons possible. In the first phase of the present study, estimated HLA haplotype frequencies in stem cell donor registries of Finland and its neighbors Sweden and Russia were calculated using the algorithm of Germany's Zentrale Knochenmarkspender-Register Deutschland and their frequencies were compared with one another and also with that of Germany. Read More

    Second Hematopoietic Stem Cell Transplant for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan-Based Conditioning Regimen.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Department of Haematology, Christian Medical College and Hospital, Vellore, India. Electronic address:
    Graft rejection (GR) after allogeneic stem cell transplantation (allo-SCT) occurs in 10% to 20% of patients with β-thalassemia major (TM). There are limited data on the clinical profile and long-term outcome of patients who have had a GR. We undertook a retrospective analysis of patients who had a graft failure after allo-SCT for TM at our center. Read More

    Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California; Department of Pediatrics, City of Hope National Medical Center, Duarte, California.
    Reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HCT) can reduce morbidity and mortality, but patients with advanced disease may require alternative approaches. In an initial report of RIC with fludarabine (FLU) and melphalan (MEL) with total marrow lymphoid irradiation (TMLI) in HCT for advanced hematologic malignancies in 33 patients, we found that the addition of TMLI to RIC was feasible and safe. Here we report long-term outcomes for these patients. Read More

    Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Department of Hematology, DAME, University of Udine, Udine, Italy.
    We report the long-term clinical outcomes of a retrospective multicenter study that enrolled 169 patients with multiple myeloma (MM) in first relapse after failing autologous stem cell transplantation (SCT). After HLA typing at relapse, 79 patients with a suitable donor, 72 (91%) of whom eventually underwent salvage allogeneic SCT (allo-SCT), were compared with 90 patients without a donor who were treated with multiple lines of salvage treatment with bortezomib and/or immunomodulatory agents. At a median follow-up of 30 months (range, 2-180 months) for all patients and 110 months (range, 38-180 months) for surviving patients, 7-year progression-free survival (PFS) was 18% in the donor group and 0% in the no-donor group (hazard ratio [HR], 2. Read More

    Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.
    Biol Blood Marrow Transplant 2017 Oct 13. Epub 2017 Oct 13.
    Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida; Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, Florida. Electronic address:
    Prognostic biomarkers in allogeneic hematopoietic cell transplantation (allo-HCT) are needed to improve risk assessment and help guide therapeutic and surveillance strategies to mitigate the risk of death from the procedure. We previously identified hypoalbuminemia at day +90 post-transplantation as an independent predictor of increased nonrelapse mortality (NRM) and inferior overall survival (OS) in patients with acute myelogenous leukemia and myelodysplastic syndrome who were treated with an allo-HCT. Here, we aim to confirm the prognostic significance of day +90 hypoalbuminemia in 783 patients, median age 52 years (range, 18 to 76), who received an allo-HCT for various hematologic malignancies and bone marrow failure syndromes. Read More

    Effect of Antithymocyte Globulin Source on Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Severe Aplastic Anemia.
    Biol Blood Marrow Transplant 2017 Oct 13. Epub 2017 Oct 13.
    State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China.
    We wanted to evaluate efficacy of porcine antithymocyte globulin (ATG) in HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation (MSD-HSCT) for patients with severe aplastic anemia (SAA). The clinical data of 113 SAA patients who received MSD-HSCT from January 2005 to November 2016 were analyzed retrospectively. Of these, 58 patients received rabbit ATG as a part of conditioning regimen (R-ATG group), whereas the other 55 patients received porcine ATG (P-ATG group). Read More

    Building a Safer and Faster CAR: Seatbelts, Airbags and Crispr.
    Biol Blood Marrow Transplant 2017 Oct 12. Epub 2017 Oct 12.
    Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Therapeutic T cell engineering has recently garnered widespread interest owing to the success of CD19 (Chimeric Antigen Receptor) CAR therapy. CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced. CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia and non-Hodgkin lymphoma. Read More

    Virus Specific T Cells: Broadening Applicability.
    Biol Blood Marrow Transplant 2017 Oct 11. Epub 2017 Oct 11.
    Children's National and The George Washington University, Washington DC.
    Virus infection still remains an appreciable cause of morbidity and mortality after Hematopoietic stem cell transplant (HSCT). While pharmacotherapy and/or antibody therapy may help to prevent or treat viral disease, these drugs are expensive, toxic and often ineffective due to primary or secondary resistance. Further, effective treatments are limited for many infections (e. Read More

    Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.
    Biol Blood Marrow Transplant 2017 Oct 9. Epub 2017 Oct 9.
    U.O. Ematologia, Ospedale Policlinico San Martino, Genova, Italy.
    We studied the impact of HLA mismatching on the outcome of 318 consecutive patients who received an unmanipulated haploidentical bone marrow transplant, followed by post-transplant cyclophosphamide (PTCy). The number of HLA-mismatched antigens was tested for its impact on overall survival (OS) and nonrelapse mortality (NRM), whereas HLA mismatches in the graft-versus-host (GVH) direction were tested for prediction of graft-versus-host disease (GVHD and relapse. Finally, we studied whether graft rejection correlated with the number of HLA mismatched antigens in host-versus-graft (HVG) direction. Read More

    Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 9. Epub 2017 Oct 9.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.
    Mucosal-associated invariant T (MAIT) cells express a semi-invariant Vα7.2(+) TCR that recognizes ligands from distinct bacterial and fungal species. In neonates, MAIT cells proliferate coincident with gastrointestinal (GI) bacterial colonization. Read More

    Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
    Biol Blood Marrow Transplant 2017 Oct 4. Epub 2017 Oct 4.
    Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
    Before the introduction of "new drugs," we designed a trial in which 162 newly diagnosed myeloma patients were biologically randomized to receive either an autologous stem cell transplant (auto-SCT) followed by a nonmyeloablative allogeneic stem cell transplant (allo-SCT) or a double auto-SCT. Fifty-eight patients in the allo-SCT arm and 46 in the double auto-SCT arm completed the assigned treatment. At a median follow-up of 12. Read More

    Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 3. Epub 2017 Oct 3.
    Allogeneic Blood and Marrow Transplant Program, Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
    Allogenic hematopoietic stem cell transplant (HCT) recipients are at risk of many infections. Nontuberculous mycobacteria (NTM) are increasingly recognized as clinically significant pathogens in this population. We investigated the incidence and risk factors for NTM infection after allogeneic HCT. Read More

    Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.
    Biol Blood Marrow Transplant 2017 Oct 3. Epub 2017 Oct 3.
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
    Cytomegalovirus (CMV) infection can increase the morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Because of a higher degree of immunosuppression, haploidentical transplant recipients may be at an increased risk of viral infections, particularly CMV. We retrospectively analyzed 86 haploidentical HCT recipients at our institution to determine whether a more intensified antiviral strategy would reduce the incidence of CMV reactivation compared with a traditional antiviral prophylaxis regimen. Read More

    Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.
    Biol Blood Marrow Transplant 2017 Sep 29. Epub 2017 Sep 29.
    Fred Hutchinson Cancer Research Center, the University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, Washington. Electronic address:
    Hematopoietic cell transplantation (HCT) provides potentially curative treatment for patients with myelofibrosis (MF). HCT outcomes are associated with the Dynamic International Prognostic Scoring System (DIPSS) risk scores. In the present study we analyzed results in 233 patients to determine if the DIPSS plus classification, which adds cytogenetics, thrombocytopenia, and RBC transfusion dependence as risk factors, would better predict post-HCT outcomes than the original DIPSS. Read More

    Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand.
    Biol Blood Marrow Transplant 2017 Sep 28. Epub 2017 Sep 28.
    Department of Haematology and BMT, Royal Melbourne Hospital, Parkville Victoria, Australia.
    We conducted a study to analyze and report on indicators of hematopoietic cell transplant (HCT) physician time use and HCT center output measures. HCT centers in Australia and New Zealand (A&NZ) were invited to provide demographic and time use details for physicians participating in HCT patient care (HCT physicians). Resource details for adult and pediatric centers were included. Read More

    Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients.
    Biol Blood Marrow Transplant 2017 Sep 28. Epub 2017 Sep 28.
    National Marrow Donor Program, Minneapolis, Minnesota.
    Patient-centered medical home models are fundamental to the advanced alternative payment models defined in the Medicare Access and Children's Health Insurance Plan Reauthorization Act (MACRA). The patient-centered medical home is a model of healthcare delivery supported by alternative payment mechanisms and designed to promote coordinated medical care that is simultaneously patient-centric and population-oriented. This transformative care model requires shifting reimbursement to include a per-patient payment intended to cover services not previously reimbursed such as disease management over time. Read More

    1 OF 79